Navigation Links
Materia Licenses Metathesis Catalyst Platform to Eisai

PASADENA, Calif.--(BUSINESS WIRE)--Jun 20, 2007 - Materia, Inc., a catalyst technology company, announced today the licensing of its metathesis platform to Eisai Co., Ltd., a leading Japanese pharmaceutical company, for use in drug discovery and development. The non-exclusive license agreement provides rights to discover, develop, and patent pharmaceutical compounds and related processes using the Company's catalysts and associated intellectual property.

Metathesis catalysts enable the formation and manipulation of carbon-carbon bonds in the synthesis of entirely new pharmaceutical products with superior properties as well as in the development of new, more efficient and low cost production processes for existing products. Materia's catalysts include those from Professor Robert Grubbs at Caltech who won the Nobel Prize for the technology in 2005.

"We are pleased that Eisai accepts the value of Materia's technology in drug discovery and process chemistry and look forward to its exciting progress," stated Dr. Michael Giardello, Materia's Chief Executive Officer. "We believe that this agreement further validates metathesis' broad potential for the pharmaceutical industry and Materia's unique intellectual property and position as the partner of choice."

About Materia

Materia was founded in 1998 to commercialize olefin metathesis catalyst technology. This market-enabling, Nobel Prize winning, green chemical technology enables chemical compounds to be synthesized with greater efficiency, under less stringent reaction conditions, and with reduced byproducts and hazardous waste. As stated by the Royal Swedish Academy of Sciences when awarding the 2005 Nobel Prize, "metathesis is an example of how important basic science has been applied for the benefit of man, society, and the environment." For more information, visit: www.materia-inc.com.

Contact

Materia, Inc.
John Kibler, 626- 584-8400


'"/>




Related medicine technology :

1. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
4. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
5. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
6. AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical Pipeline to Be Featured at AACR
7. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... 2, 2016 Kalorama Information noted the 5 ... market in a recent white paper.  The healthcare market ... usage, a growing market are among the top drivers ... report EMR 2016: The Market for Electronic ... complete study of the EMR industry, and the report ...
(Date:5/2/2016)... LAWRENCEVILLE, N.J. , May 2, 2016 /PRNewswire/ ... drug development company, today announced data from the ... dose escalating clinical trial (the OVATION Study) combining ... of care for the treatment of newly-diagnosed patients ... chemotherapy followed by interval debulking surgery.  In the ...
(Date:4/29/2016)... ISELIN, New Jersey , April 29, 2016 ... Omnichannel Software Suite for Life Sciences, Product Development ... and Global Life Science Customer Base . ... healthcare solutions provider, today announced the acquisition of ... is a global leader in adaptive sales enablement ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Nationally recognized personal injury law firm Monge & ... giving free roses to anyone who wants one for their Mother or any other mother ... important valuable contributions of Mothers.” Monge goes on to say, “we are choosing to ...
(Date:5/3/2016)... ... May 03, 2016 , ... United Benefit Advisors (UBA), ... as the latest addition to its elite stable of Partner Firms. Benefits Alliance ... David Styles, and Paul Vincent. The Firm is also led by industry and ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... Dr. ... promotions on cosmetic dental treatments to both new and existing patients. Cosmetic dentistry allows ... option for patients who have healthy smiles with some minor or more serious cosmetic ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... remote access connectivity solutions, today announced the new SecureAccess feature for its ... new Celestix SecureAccess release will enable organizations to get the DirectAccess user ...
(Date:5/3/2016)... ... 03, 2016 , ... The new web-based solution HIPAA ... practices, to better grasp and implement HIPAA’s privacy, security, and data breach requirements. ... well-defined, expert-created path to compliance. HIPAA Institute has positioned itself to be an ...
Breaking Medicine News(10 mins):